GLS and neoplasm: Chemical inhibition of key points of glutamine metabolism, such as GLS and MYC, or genetic knockdown of these genes and glutamine transporters, suppresses glutamine decomposition, thereby inhibiting crucial CSC-driving pathways (WNT/β-catenin, the oxidative stress response, and the DNA damage response), resulting in CSC depletion both in vitro and in vivo and enhancing tumor radiosensitivity.